Is natalizumab a safe treatment for patients with multiple sclerosis in the COVID-19 pandemic? Data from the first year of the pandemic

BACKGROUND: Patients with MS have increased risk of infections, especially those with highly active treatments. We studied the safety of natalizumab in patients with MS during the COVID-19 pandemic. METHODS: Demographic features, time on natalizumab, dose interval and COVID-19 symptoms were evaluate...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mult Scler Relat Disord
Autores principales: Díaz-Díaz, Judit, Ramirez, Clara Isabel, Ortiz-Pica, Marta, García-Yusta, Elena, Gómez-Estevez, Irene, Oreja-Guevara, Celia
Formato: Artigo
Lenguaje:Inglês
Publicado: Published by Elsevier B.V. 2021
Materias:
Topic: Management of MS during the COVID-19 pandemic
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8250634/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2021.102994
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares